Roundhill Investments launches GLP-1 & Weight Loss ETF (OZEM) with major holdings in Eli Lilly and Novo Nordisk.
Top ETF provider Roundhill Investments launches GLP-1 & Weight Loss ETF (OZEM) focusing on GLP-1 weight loss drugs, with major players Eli Lilly and Novo Nordisk holding ~20% weightings each. CEO Dave Mazza highlights the fund's potential for explosive growth in the industry. Both Eli Lilly and Novo Nordisk have seen significant share price increases, with Lilly's up 90% in the past year.
May 27, 2024
5 Articles